Finasteride, which is marketed under the brand names Propecia and Proscar, and some others, is a medication largely used to treat hair loss or enlarged prostate in men. The drug prevents the conversion of testosterone to dihydrotestosterone (DHT), which is a leading factor for the development of benign prostatic hyperplasia (BPH) and androgenic alopecia, also known as male pattern baldness (MPB). Propecia is used in the treatment of male pattern hair loss in men whereas Proscar is used to treat the symptoms of BPH.
With growing focus on haircare, a large number of men are willing to spend heavily on haircare products. These trends will undeniably propel the adoption of finasteride in the future. It is estimated that global finasteride market size will exceed a valuation of more than US$130 million by 2026, with increasing occurrence of male pattern baldness and BPH across the globe.
Get sample copy of this research report @ https://www.gminsights.com/request-sample/detail/732
Growing global occurrence of male pattern baldness
Male pattern baldness, biologically known as androgenic alopecia, is responsible for most cases of hair loss in men. There are many possible reasons that cause hair loss in men, including, extremely stressful events, occurrence of a serious disease, and reaction to certain medication. However, a vast majority of hair loss in men is due to heredity and genetics.
According to America Hair Loss Association (AHLA), androgenic alopecia is responsible for more than 95% of hair loss in men. AHLA reports that more than two-thirds of Americans will experience of some degree of noticeable hair loss by the age of 35.
Over the past several years, medicine has made considerable strides in the treatment of male pattern hair loss. The U.S. Food and Drug Administration (FDA) had approved 1mg dosage of finasteride (Propecia) for the treatment of male pattern baldness in men. Evidently, Propecia is the first drug so far to effectively treat androgenic alopecia in most of the men who use it.
Widespread use to treat the symptoms of BPH in men
Benign prostatic hyperplasia (BPH), commonly known as prostate gland enlargement, is a common and prevailing condition in older men. BPH is not the same as prostate cancer and neither does it increase the risk of prostate cancer. However, it affects a large percentage of the global male population and negatively impacts their quality of life.
Statistical figures show that almost half of all men aged between 51 and 60 show symptoms of BPH and approximately 90% of men aged 80 or more have it. It is estimated that nearly 30 million men worldwide have symptoms associated with BPH.
Proscar is an FDA-approved drug for the treatment of symptomatic BPH in men with enlarged prostate gland to alleviate symptoms, minimize the rise of acute urinary retention, and eliminate the need for surgery including prostatectomy and transurethral resection of the prostate (TURP).
Request for customization of this report @ https://www.gminsights.com/roc/732
Some key factors impacting the demand for finasteride market
Several potential side-effects associated with the administration of finasteride tablets might limit and hamper their demand in the future. However, a growing prevalence of BPH and prostate cancer worldwide will ensure the product adoption. Recent years have witnessed increased spending my men on haircare products which can also be a major factor boosting the adoption of finasteride tablets to treat male pattern baldness.
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
